BGBIO Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
BerGenBio ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 9.02 |
| 52 Week High | NOK 23.70 |
| 52 Week Low | NOK 5.62 |
| Beta | 1.51 |
| 1 Month Change | 5.47% |
| 3 Month Change | -9.61% |
| 1 Year Change | -60.44% |
| 3 Year Change | -99.44% |
| 5 Year Change | -99.40% |
| Change since IPO | -99.64% |
Recent News & Updates
Recent updates
We Think BerGenBio (OB:BGBIO) Needs To Drive Business Growth Carefully
Jan 06
Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?
Sep 21Companies Like BerGenBio (OB:BGBIO) Could Be Quite Risky
Jun 02Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely
Dec 07BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely
Aug 24BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely
Feb 06Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?
Sep 26Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?
Jun 11Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?
Feb 17We're Not Very Worried About BerGenBio's (OB:BGBIO) Cash Burn Rate
Sep 21It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year
Mar 13We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow
Feb 11What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)?
Dec 21Shareholder Returns
| BGBIO | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | 16.0% | 0.1% | 0.5% |
| 1Y | -60.4% | -58.0% | 9.0% |
Return vs Industry: BGBIO underperformed the Norwegian Biotechs industry which returned -58% over the past year.
Return vs Market: BGBIO underperformed the Norwegian Market which returned 9% over the past year.
Price Volatility
| BGBIO volatility | |
|---|---|
| BGBIO Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 14.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in NO Market | 12.9% |
| 10% least volatile stocks in NO Market | 2.6% |
Stable Share Price: BGBIO's share price has been volatile over the past 3 months compared to the Norwegian market.
Volatility Over Time: BGBIO's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 15 | Olav Hellebo | www.bergenbio.com |
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company’s lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors.
BerGenBio ASA Fundamentals Summary
| BGBIO fundamental statistics | |
|---|---|
| Market cap | NOK 277.52m |
| Earnings (TTM) | -NOK 152.29m |
| Revenue (TTM) | NOK 521.00k |
676.7x
P/S Ratio-2.3x
P/E RatioIs BGBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BGBIO income statement (TTM) | |
|---|---|
| Revenue | NOK 521.00k |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 521.00k |
| Other Expenses | NOK 152.81m |
| Earnings | -NOK 152.29m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 26, 2025
| Earnings per share (EPS) | -3.90 |
| Gross Margin | 100.00% |
| Net Profit Margin | -29,230.13% |
| Debt/Equity Ratio | 0% |
How did BGBIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 19:06 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BerGenBio ASA is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ulrik Trattner | Carnegie Investment Bank AB |
| Patrik Ling | DNB Markets |
| Geir Holom | DNB Markets |